Navigation Links
Implanted Sleep Device Shows Promising Early Results
Date:5/17/2010

ST. PAUL, Minn. and NEW ORLEANS, May 17 /PRNewswire/ -- Apnex Medical announced today that preliminary data from a first-in-man clinical study showed significant improvements in sleep for people suffering from obstructive sleep apnea (OSA). The Apnex HGNS™ System, developed by the St. Paul-based company, is a device designed to treat OSA, which is a serious life-threatening illness characterized by fragmented sleep and excessive day-time sleepiness. The HGNS System activates an upper airway muscle during sleep, which opens the airway, allowing patients to breathe and remain asleep.

"These results demonstrate the potential benefits the HGNS System could provide to patients who do not tolerate continuous positive airway pressure (CPAP) therapy," said Peter Eastwood, Ph.D., Senior Research Fellow at the West Australian Sleep Disorders Research Institute, Sir Charles Gairdner Hospital, Professor at the School of Anatomy and Human Biology, University of Western Australia, and an investigator with this study. "In most patients, the Apnex HGNS System reduced the severity of their OSA condition, allowing them to sleep better and feel better."

Three- and six-month data from the Australian first-in-man study evaluating the safety and efficacy of the HGNS System were presented today by Dr. Eastwood, as part of the session, "New Treatment Approaches for Lung Disease: Late Breaking Abstracts," at the American Thoracic Society (ATS) 2010 International Conference. The findings show the HGNS System reduced the severity of OSA by an average of over 50%, as measured by the apnea-hypopnea index (AHI). AHI measures the number of times per hour during sleep that a person either stops breathing or has restricted breathing. Patients also experienced significant improvements in symptoms, as measured by multiple quality of life surveys. Patients tolerated the treatment well, with an average of 6.5 hours of use each night. There were no device failures during the study.

"These data give us confidence that the HGNS System works, patients use it, and patients sleep better because of it," said Robert Atkinson, Apnex Medical president and chief executive officer. "They have improved oxygen levels during sleep and are waking up less, which we believe can lead to better overall health. We are learning a tremendous amount about this new therapy, which we believe will lead to even better outcomes through therapy adjustment and patient selection. We are excited about our on-going clinical trials in the United States and Australia, the results of which will support future applications for commercial approval."

About Apnex Medical and HGNS System

Apnex Medical was founded in 2006 with a mission to pioneer medical innovations to improve the health of people with sleep disordered breathing. The company has developed a proprietary medical device for the treatment of OSA.

The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that activates an upper airway muscle to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device automatically turns on when the patient is sleeping and turns off when the patient is awake.

About OSA

According to the World Health Organization, approximately 100 million people worldwide have OSA. In the United States, symptomatic OSA affects 1 in 4 men and 1 in 9 women. It most often occurs when the airway muscles fail to keep the airway open during sleep. Untreated OSA increases the risk of death; as well as stroke, high blood pressure, coronary artery disease, heart failure and diabetes. It causes fragmented sleep, which leads to excessive daytime sleepiness, resulting in an increased risk of accidents and lost productivity. Current OSA treatments are not always successful or well tolerated. The Apnex HGNS System is designed to provide an alternative treatment for OSA that addresses these problems.

About US Clinical Study

The Apnex HGNS System is currently being evaluated in a clinical study in the United States. The overall purpose of the study is to demonstrate the safety and effectiveness of system in treating OSA. Additional information on the HGNS System and US clinical study is available on the Apnex Medical website at www.apnexmedical.com. There is a sign-up option for anyone interested in receiving Apnex Medical news updates or being provided more information on the clinical study.

About American Thoracic Society

The American Thoracic Society (ATS) is a non-profit, international, professional and scientific society for respiratory, critical care and sleep medicine. The ATS is committed to the prevention and treatment of respiratory disease through research, education, patient care and advocacy. The long-range goal of the ATS is to decrease morbidity and mortality from respiratory, critical care and sleep disorders and life threatening acute illnesses in people of all ages. In keeping with these goals, ATS interacts with both national and international organizations which have similar goals. For more information, visit www.thoracic.org.

CAUTION: The Apnex HGNS System is an investigational device and is limited by Federal Law to investigational use.

FOR CLINICAL TRIAL USE ONLY.

Apnex Medical and HGNS are trademarks of Apnex Medical, Inc.

© Apnex Medical, Inc. 2010. All rights reserved.


'/>"/>
SOURCE Apnex Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial
2. American Heart Association Rapid Access Journal Report: Implanted Monitor Accurately Detects Heart Rhythm Disturbances
3. FDA Approves First Totally Implanted Hearing System
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
6. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
7. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
8. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
9. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
10. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
11. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 Mosaic Life Care, based in St. Joseph, ... process across its network of 58 clinics, located in 22 cities, and its flagship ... innovative ways to improve the delivery of health care to its patients, including the ... ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... March 23, 2017 ... created through extensive primary research (inputs from industry ... aims to present the analysis of global heart ... (Replacement and Repair); Replacement Procedure By Technique (Mechanical, ... Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral Valve ...
(Date:3/23/2017)... -- Summary Global Markets ... Primary Hyperoxaluria - Pipeline Review, H1 2017, provides ... System And Sex Hormones) pipeline landscape. Primary ... kidney and bladder stones. It results from the ... blood in the urine, pain when urinating, fever, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
(Date:3/23/2017)... New York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are ... every 3 kids do not brush their teeth the minimum two times a day that ... teeth; with students missing 51 million hours of school and adults missing 164 million hours ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
(Date:3/23/2017)... ... 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle ... , “We’re excited to be operating on U.S. shores, where most of our initial ...
Breaking Medicine News(10 mins):